These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 33758605)

  • 1. Prognostic efficacy of the combination of the pretreatment systemic Immune-Inflammation Index and Epstein-Barr virus DNA status in locally advanced Nasopharyngeal Carcinoma Patients.
    Xiong Y; Shi LL; Zhu LS; Ding Q; Ba L; Peng G
    J Cancer; 2021; 12(8):2275-2284. PubMed ID: 33758605
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic value of pretreatment prognostic nutritional index and lactated dehydrogenase in locally advanced nasopharyngeal carcinoma patients.
    Xiong Y; Shi LL; Zhu LS; Peng G
    Ann Palliat Med; 2021 Apr; 10(4):4122-4133. PubMed ID: 33832314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of immune-inflammatory and nutrition indicators in non-metastatic nasopharyngeal carcinoma with negative plasma Epstein-Barr virus DNA.
    Weng Y; Wu L; Li Y; Wang J; Wu Z; Hong X; Liu X; Lai J; Lu J; Qiu S
    Ther Adv Med Oncol; 2024; 16():17588359241286489. PubMed ID: 39403452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of systemic inflammation response index in nasopharyngeal carcinoma with negative Epstein-Barr virus DNA.
    Yuan X; Yang H; Zeng F; Zhou S; Wu S; Yuan Y; Cui L; Feng H; Lin D; Chen Z; Liu X; Chen J; Wang F
    BMC Cancer; 2022 Aug; 22(1):858. PubMed ID: 35932022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and Validation of Nomogram Based on Combination of Pretreatment C-Reactive Protein/Albumin Ratio-EBV DNA Grade in Nasopharyngeal Carcinoma Patients Who Received Concurrent Chemoradiotherapy.
    Huang ZZ; Wen W; Hua X; Song CG; Bi XW; Huang JJ; Xia W; Yuan ZY
    Front Oncol; 2021; 11():583283. PubMed ID: 34336633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
    Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
    Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nomogram incorporating Epstein-Barr virus DNA and a novel immune-nutritional marker for survival prediction in nasopharyngeal carcinoma.
    Wu S; Yuan X; Huang H; Li Y; Cui L; Lin D; Lu W; Feng H; Chen Z; Liu X; Tan J; Wang F
    BMC Cancer; 2023 Dec; 23(1):1217. PubMed ID: 38066499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
    Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
    JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a Prognostic Nomogram for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Incorporating TNM Stage, Post-Induction Chemotherapy Tumor Volume and Epstein-Barr Virus DNA Load.
    Jiang YT; Chen KH; Yang J; Liang ZG; Qu S; Li L; Zhu XD
    Front Oncol; 2021; 11():683475. PubMed ID: 34222003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma.
    Zhang J; Peng H; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
    BMC Cancer; 2018 Dec; 18(1):1276. PubMed ID: 30567511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
    Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
    Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic immune-inflammation index during treatment predicts prognosis and guides clinical treatment in patients with nasopharyngeal carcinoma.
    Yuan X; Feng H; Huang H; Li J; Wu S; Yuan Y; Cui L; Lin D; Chen Z; Lu W; Liu X; Peng X; Wang F
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):191-202. PubMed ID: 36595043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy.
    Hua X; Li WZ; Huang X; Wen W; Huang HY; Long ZQ; Lin HX; Yuan ZY; Guo L
    Front Oncol; 2021; 11():625534. PubMed ID: 33777769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.
    Li J; Chen S; Peng S; Liu Y; Xing S; He X; Chen H
    Int J Biol Sci; 2018; 14(5):549-556. PubMed ID: 29805306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
    Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of a combined and controlled nutritional status score and EBV-DNA in patients with advanced nasopharyngeal carcinoma: a long-term follow-up study.
    Lu H; Guo S; Liu L; Chen Q; Liang Y; Liu S; Sun X; Tang Q; Li X; Guo L; Mo H; Tang L; Mai H
    Cancer Biol Med; 2021 Jun; 19(4):551-64. PubMed ID: 34132505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of inflammation-based prognostic index in patients with nasopharyngeal carcinoma: a propensity score matching study.
    Oei RW; Ye L; Kong F; Du C; Zhai R; Xu T; Shen C; Wang X; He X; Kong L; Hu C; Ying H
    Cancer Manag Res; 2018; 10():2785-2797. PubMed ID: 30147375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of EBV DNA and platelet-to-lymphocyte ratio in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.
    Dong H; Huang Z; Yang D; Li Z; Huang H; Meng Z; Qin Y; Kang M
    BMC Cancer; 2023 Jul; 23(1):673. PubMed ID: 37464319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of pan-immune-inflammation value (PIV) in nasopharyngeal carcinoma patients.
    Zhang N; Hou T; Zhang S; Ling J; Jiang S; Xie Y; Liu X; Hu C; Feng Y
    Heliyon; 2024 Jan; 10(2):e24804. PubMed ID: 38312571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin.
    Hua L; Chen S; Wei M; Shen Y; Long J; Lin Z; Meng Y; Guo C; Huang H; Tu X; Yao M
    Cancer Biother Radiopharm; 2022 Feb; 37(1):2-10. PubMed ID: 33764811
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.